Critical Outcome Investor Presentation - March 2014
of 17
/17
-
Upload
critical-outcome-technologies-inc -
Category
Investor Relations
-
view
607 -
download
0
Embed Size (px)
description
Transcript of Critical Outcome Investor Presentation - March 2014
Investor Presentation | March 2014
The future of drug discovery has arrived
Reducing development time, cost & risk
2 TSXV: COT
When used anywhere in this presentation, whether oral or written, the words expects, believes, anticipates, estimates and similar expressions are intended to identify forward-looking statements. Forward-looking statements may include statements addressing future financial and operating results of Critical Outcome Technologies Inc. (COTI).
COTI bases these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of COTI’s strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of potential patent issues, competition, changes in economic conditions, and other risks described in COTI’s public documents such as press releases and filings with the Toronto Stock Exchange and the Ontario Securities Commission.
All forward-looking statements are qualified in their entirety by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this presentation. These forward-looking statements speak only as of the date of this presentation.
Disclaimer
3 TSXV: COT
3 TSXV: COT
Critical Outcome Technologies Inc.
3
A bioinformatics and accelerated drug discovery company
Listed on the TSX-V under the symbol COT since 2006
4 TSXV: COT
Investment highlights
1
2
3
We reduce the time, cost & risk of bringing new drugs to market
Potential cancer breakthrough drug candidate is nearly Phase 1 ready
We have many more revenue opportunities in our pipeline
5 TSXV: COT
Conventional drug development is a long & expensive process characterized by a high risk of failure
11 – 15 years
$1 billion or more
1 FDA approval 5
6 TSXV: COT
What we do
Reduce drug discovery, optimization & lead selection by 1.5 to 3 yrs.
Saving significant $$$
Increasing revenue period under patent protection
7 TSXV: COT
How we do it – CHEMSAS®
7 TSXV: COT
Proprietary, artificial intelligence based drug discovery platform technology
8 TSXV: COT
Failed attempts occur quickly & cheaply in computer simulations, not the ‘wet lab’
Higher probability of clinical & commercial success
Computational replication of traditional ‘wet lab’ drug discovery process
8
Advantages of CHEMSAS®
TSXV: COT
9 TSXV: COT
Potential cancer breakthrough
Our lead compound, COTI-2, is effective against cancers with mutations of the p53 gene
10 TSXV: COT
Why COTI-2 is exciting
> 50% of all human cancers have a p53 mutation (eg. ~ 95% of ovarian cancers)
Mechanism of action confirmed by thought leader Dr. Gordon Mills at MD Anderson Cancer Center (June 2013)
Novel, first-in-class
Strong IP protection in place
11 TSXV: COT
COTI-2 is (nearly) Phase 1 ready
In final 2-species toxicity studies – completion in first half of 2014
FDA IND filing expected in second half of 2014 (leading to Phase 1 clinical trial)
Pursuing orphan drug and/or breakthrough therapy status
Signed an LOI with a strategic partner, Portage Biotech Inc., for clinical development
12 TSXV: COT TSXV: COT
COTI-2 = significant revenue potential
Top 5 2012 Phase 1/2 oncology licensing deals disclosed (1):
Upfront payments of approx. $25-$92 million
Milestone payments between $550-$1,100 million
Royalties on net sales
1st half of 2013 (2) – 16 Phase 1 licensing deals with 6 in cancer – avg. upfront $30m
(1) Medius Associates (2) Thomson Reuters
13 TSXV: COT
Other revenue opportunities
Robust internal pipeline of compounds
- AML, colorectal cancer, small cell lung cancer library, MS, etc.
3 existing R&D collaborations expected to bring in milestone payments beginning late 2014 / 2015
- Western University
- Delmar Chemicals
- Major Pharma Co.
14 TSXV: COT
14 TSXV: COT
Looking ahead
14
Other CHEMSAS® applications:
CHEMFirm – Small molecule profiling & investment due diligence tool
Drug library profiling – Based on customer identified criteria
Drug repurposing – Finding new purposes for drugs coming off patent
15 TSXV: COT
15 TSXV: COT
Project ROSALIND
15
Programmable computer simulation of human cancer cell signaling
Better personalized treatment decisions based on genetic profile of one’s cancer
Personalized cancer gene profiling projected to be ~ $35B market by 2018
*
* Markets and Markets (2013)
16 TSXV: COT
Summary
1
2
3
We reduce the time, cost & risk of bringing new drugs to market
Potential cancer breakthrough drug candidate is nearly Phase 1 ready
We have many more revenue opportunities in our pipeline
The future of drug discovery has arrived
Reducing development time, cost & risk
Dr. Wayne Danter President & CEO Tel: (519) 858-5157 [email protected]
www.criticaloutcome.com www.facebook.com/criticaloutcome twitter.com/criticaloutcome www.slideshare.net/criticaloutcome
